New Company Emerges to Fight Rare Disease
A new company, Ambros Therapeutics, forms to push a promising drug for a rare genetic disease closer to approval.
A big change just happened in the world of medicine. A company named Werewolf Therapeutics has teamed up with a new group. They will now be known as Ambros Therapeutics. This new company has a clear goal: to bring an important drug to patients who need it.
Ambros Therapeutics works on a rare genetic disease. This disease, called phenylketonuria or PKU, affects how the body breaks down food. Patients with PKU must follow a very strict diet. The new company just raised $150 million. This money will help them finish testing their drug.
The drug is now in its final testing stage. This stage is called Phase 3. If these tests go well, the drug can get approval. This means patients could soon have a new way to manage PKU. It offers a lot of hope for those families.
Source: FierceBiotech
More from Biotech
